Efficacy and Safety of Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients with Type 2 Diabetes Mellitus: A Randomized Placebo-Controlled Study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
There is a growing interest in cell-based therapies in T2DM as β-cell failure is progressive and inexorable with the advancing duration of disease. This prospective, randomized, single-blinded placebo-controlled study evaluates the efficacy and safety of autologous bone marrow-derived stem cell transplantation (ABMSCT) in T2DM. Twenty-one patients with triple oral antidiabetic drug failure and requiring insulin ≥0.4 IU per kg per day with HbA1c <7.5% were randomly assigned to an intervention ( n = 11) and control group ( n = 10) and followed for 12 months. Patients in the intervention group received ABMSCT through a targeted approach, and after 12 weeks, a second dose of stem cells was administered through the antecubital vein after mobilization with G-CSF, while the control group underwent a sham procedure. The primary end point was a reduction in insulin requirement by ≥50% from baseline while maintaining HbA1c <7%. Nine out of the 11 (82%) patients in the intervention group achieved the primary end point, whereas none of the patients in the control group did over the study period ( p = 0.002). The insulin requirement decreased by 66.7% in the intervention group from 42.0 (31.0-64.0) IU per day to 14.0 (0.0-30.0) IU per day ( p = 0.011), while in controls it decreased by 32.1% from 40.5 (31.8-44.3) IU per day to 27.5 (23.5-33.3) IU per day ( p = 0.008) at 12 months. The reduction in insulin requirement was significantly more in the intervention group compared to controls at both 6 ( p = 0.001) and 12 months ( p = 0.004). There was a modest but nonsignificant increase in HbA1c (%) in cases from 6.9% (6.4-7.2%) to 7.1% (6.6-7.5%) as well as in controls from 6.9% (6.2-7.0%) to 7.0% (6.9-7.5%). Ten out of 11 (91%) patients could maintain HbA1c <7% in the intervention group, whereas 6 out of 10 did (60%) in the control group ( p = 0.167). The glucagon-stimulated C-peptide significantly increased in treated cases compared to controls ( p = 0.036). The decrease in insulin requirement positively correlated with stimulated C-peptide ( r = 0.8, p = 0.001). In conclusion, ABMSCT results in a significant decrease in the insulin dose requirement along with an improvement in the stimulated C-peptide levels in T2DM. However, a greater number of patients with a longer duration of follow-up are required to substantiate these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Glycemic Characteristics in Continuously Monitored Patients With Type 1 and Type 2 Diabetes
Bode, B. W., Schwartz, S., Stubbs, H. A., & Block, J. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2361 · Cited by 137
Deteriorating beta–cell function in type 2 diabetes: a long–term model
Bagust, A., & Beale, S. (2003) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcg040 · Cited by 105
Cited by
Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy
Fan, X.-L., Zhang, Y., Li, X., & Fu, Q.-L. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03454-6 · Cited by 535
Tissue Engineering and Regenerative Medicine: Achievements, Future, and Sustainability in Asia
Han, F., Wang, J., Ding, L., Hu, Y., Li, W., Yuan, Z., Guo, Q., Zhu, C., Yu, L., Wang, H., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00083 · Cited by 357
Nakamura, Y., Kita, S., Tanaka, Y., Fukuda, S., Obata, Y., Okita, T., Nishida, H., Takahashi, Y., Kawachi, Y., Tsugawa-Shimizu, Y., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.026 · Cited by 164
“A gain inMSCs is beneficial in a variety of diseases, including graft-versus-host disease,(19) heart disease,(20) type 1 diabetes,(21) and type 2 diabetes.(22) According to the public clinical trials database,(23) more than 893 clinical trials have, so far, used MSCs in the treatment of diverse diseases.”
BackgroundBhansali, S., Dutta, P., Kumar, V., Yadav, M. K., Jain, A., Mudaliar, S., Bhansali, S., Sharma, R. R., Jha, V., Marwaha, N., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0275 · Cited by 126
Self-citationYazhen, Z., Wenyi, C., Bing, F., & Hongcui, C. (2020) · Aging and disease · doi:10.14336/ad.2019.0421 · Cited by 82
“Information on insulin requirement was available in five trials that included 58 patients receiving stem cell therapy [17, 23, 29, 31, 33].”
MethodInfluential
Metadata
- Authors
- Bhansali, A., Asokumar, P., Walia, R., Bhansali, S., Gupta, V., Jain, A., Sachdeva, N., Sharma, R. R., Marwaha, N., & Khandelwal, N.
- Venue
- Cell Transplantation
- Publisher
- SAGE Publications
- Published
- 2014-09
- Volume
- 23
- Issue
- 9
- Pages
- 1075-1085
- ISSN
- 0963-6897 (ISSN-L)
- 1555-3892
- OpenAlex
- W1966366851
- Cited by
- 121
- References
- 6
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.